531 related articles for article (PubMed ID: 26684558)
1. Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.
Patel RS; Scopelliti EM; Savelloni J
Pharmacotherapy; 2015 Dec; 35(12):1189-203. PubMed ID: 26684558
[TBL] [Abstract][Full Text] [Related]
2. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
Polychronopoulos G; Tziomalos K
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
[TBL] [Abstract][Full Text] [Related]
3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
Paton DM
Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
[TBL] [Abstract][Full Text] [Related]
5. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Robinson JG
J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
[TBL] [Abstract][Full Text] [Related]
6. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
8. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
Marbach JA; McKeon JL; Ross JL; Duffy D
Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
[TBL] [Abstract][Full Text] [Related]
9. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?
Sahebkar A; Watts GF
Cardiovasc Drugs Ther; 2013 Dec; 27(6):559-67. PubMed ID: 23913122
[TBL] [Abstract][Full Text] [Related]
10. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
[TBL] [Abstract][Full Text] [Related]
11. [New lipid lowering agents].
Cuevas A; Farías MM; Alonso R
Rev Med Chil; 2014 Jul; 142(7):880-8. PubMed ID: 25378007
[TBL] [Abstract][Full Text] [Related]
12. Familial hypercholesterolemia: etiology, diagnosis and new treatment options.
Gouni-Berthold I; Berthold HK
Curr Pharm Des; 2014; 20(40):6220-9. PubMed ID: 24953396
[TBL] [Abstract][Full Text] [Related]
13. Promising new therapies for the treatment of hypercholesterolemia.
Valerio MG; Velayati A; Jain D; Aronow WS
Expert Opin Biol Ther; 2016; 16(5):609-18. PubMed ID: 26822080
[TBL] [Abstract][Full Text] [Related]
14. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
Page MM; Stefanutti C; Sniderman A; Watts GF
Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 inhibition in the management of familial hypercholesterolemia.
Ogura M
J Cardiol; 2018 Jan; 71(1):1-7. PubMed ID: 28784313
[TBL] [Abstract][Full Text] [Related]
18. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
Bell DA; Hooper AJ; Watts GF; Burnett JR
Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
[TBL] [Abstract][Full Text] [Related]
19. Novel Approaches for the Treatment of Familial Hypercholesterolemia.
Bonanni L; Cutolo A; Dalla Vestra M
Exp Clin Endocrinol Diabetes; 2016 Nov; 124(10):583-587. PubMed ID: 27711959
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
Okere AN; Serra C
Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
